119 related articles for article (PubMed ID: 27177946)
1. Evaluation of various adjuvant nanoparticulate formulations for meningococcal capsular polysaccharide-based vaccine.
Gala RP; D'Souza M; Zughaier SM
Vaccine; 2016 Jun; 34(28):3260-7. PubMed ID: 27177946
[TBL] [Abstract][Full Text] [Related]
2. Induction of death receptor CD95 and co-stimulatory molecules CD80 and CD86 by meningococcal capsular polysaccharide-loaded vaccine nanoparticles.
Ubale RV; Gala RP; Zughaier SM; D'Souza MJ
AAPS J; 2014 Sep; 16(5):986-93. PubMed ID: 24981893
[TBL] [Abstract][Full Text] [Related]
3. Analysis of novel meningococcal vaccine formulations.
Zughaier SM
Hum Vaccin Immunother; 2017 Jul; 13(7):1728-1732. PubMed ID: 28394704
[TBL] [Abstract][Full Text] [Related]
4. Formulation of meningococcal capsular polysaccharide vaccine-loaded microparticles with robust innate immune recognition.
Ubale RV; D'Souza MJ; Infield DT; McCarty NA; Zughaier SM
J Microencapsul; 2013; 30(1):28-41. PubMed ID: 22657751
[TBL] [Abstract][Full Text] [Related]
5. A novel monoclonal antibody to Neisseria meningitidis serogroup X capsular polysaccharide and its potential use in quantitation of meningococcal vaccines.
Reyes F; Otero O; Camacho F; Amin N; Ramírez F; Valdés Y; Acevedo R; García L; Cardoso D; Cuello M
Biologicals; 2014 Nov; 42(6):312-5. PubMed ID: 25218518
[TBL] [Abstract][Full Text] [Related]
6. Interactions of proteoliposomes from serogroup B Neisseria meningitidis with bone marrow-derived dendritic cells and macrophages: adjuvant effects and antigen delivery.
Rodríguez T; Pérez O; Ménager N; Ugrinovic S; Bracho G; Mastroeni P
Vaccine; 2005 Jan; 23(10):1312-21. PubMed ID: 15652674
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice.
Fukasawa LO; Dias WO; Schenkman RP; Raw I; Tanizaki MM
FEMS Immunol Med Microbiol; 2004 Jul; 41(3):205-10. PubMed ID: 15196569
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines.
Sanders H; Feavers IM
Expert Rev Vaccines; 2011 Mar; 10(3):323-34. PubMed ID: 21434800
[TBL] [Abstract][Full Text] [Related]
9. Conjugation of β-glucan markedly increase the immunogencity of meningococcal group Y polysaccharide conjugate vaccine.
Qiao W; Ji S; Zhao Y; Hu T
Vaccine; 2015 Apr; 33(17):2066-72. PubMed ID: 25728319
[TBL] [Abstract][Full Text] [Related]
10. The adjuvant effect of TLR7 agonist conjugated to a meningococcal serogroup C glycoconjugate vaccine.
Donadei A; Balocchi C; Mancini F; Proietti D; Gallorini S; O'Hagan DT; D'Oro U; Berti F; Baudner BC; Adamo R
Eur J Pharm Biopharm; 2016 Oct; 107():110-9. PubMed ID: 27388628
[TBL] [Abstract][Full Text] [Related]
11. Preclinical immunogenicity study of trivalent meningococcal AWX-OMV vaccines for the African meningitis belt.
Tunheim G; Naess LM; Acevedo R; Fjeldheim ÅK; Bolstad K; García L; Cardoso D; Aase A; Zayas C; González H; Rosenqvist E; Norheim G
Vaccine; 2014 Nov; 32(49):6631-8. PubMed ID: 25305564
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
[TBL] [Abstract][Full Text] [Related]
13. MenACWY-CRM, a novel quadrivalent glycoconjugate vaccine against Neisseria meningitidis for the prevention of meningococcal infection.
Pace D
Curr Opin Mol Ther; 2009 Dec; 11(6):692-706. PubMed ID: 20072946
[TBL] [Abstract][Full Text] [Related]
14. Gel Phase 1,2-Distearoyl-
Norling K; Bernasconi V; Agmo Hernández V; Parveen N; Edwards K; Lycke NY; Höök F; Bally M
ACS Infect Dis; 2019 Nov; 5(11):1867-1878. PubMed ID: 31498993
[TBL] [Abstract][Full Text] [Related]
15. A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens.
Singh M; Ugozzoli M; Kazzaz J; Chesko J; Soenawan E; Mannucci D; Titta F; Contorni M; Volpini G; Del Guidice G; O'Hagan DT
Vaccine; 2006 Mar; 24(10):1680-6. PubMed ID: 16300864
[TBL] [Abstract][Full Text] [Related]
16. The potential of adjuvants to improve immune responses against TdaP vaccines: A preclinical evaluation of MF59 and monophosphoryl lipid A.
Agnolon V; Bruno C; Leuzzi R; Galletti B; D'Oro U; Pizza M; Seubert A; O'Hagan DT; Baudner BC
Int J Pharm; 2015 Aug; 492(1-2):169-76. PubMed ID: 26149936
[TBL] [Abstract][Full Text] [Related]
17. TLR4-dependent adjuvant activity of Neisseria meningitidis lipid A.
Zughaier S; Steeghs L; van der Ley P; Stephens DS
Vaccine; 2007 May; 25(22):4401-9. PubMed ID: 17466419
[TBL] [Abstract][Full Text] [Related]
18. AFCo1 as nasal adjuvant of capsular polysaccharide from Neisseria meningitidis serogroup C induces systemic and mucosal immune responses.
Romeu B; González E; Zayas C; Del Campo J; Acevedo R; Cuello M; Valdes Y; Balboa J; Cabrera O; Lastre M; Pérez O
Scand J Infect Dis; 2011 Oct; 43(10):809-13. PubMed ID: 21671827
[TBL] [Abstract][Full Text] [Related]
19. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
Cohen R; Levy C
Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368
[TBL] [Abstract][Full Text] [Related]
20. Meningococcal disease: a review on available vaccines and vaccines in development.
Bröker M; Fantoni S
Minerva Med; 2007 Oct; 98(5):575-89. PubMed ID: 18043565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
